Science News
from research organizations

CpG DNA Therapy For Alzheimer Disease

Date:
October 22, 2009
Source:
American Journal of Pathology
Summary:
Researchers have found that CpG DNA may be a therapeutic candidate for treatment of Alzheimer disease.
Share:
       
FULL STORY

Dr. Yukiko Doi and colleagues at Nagoya University have found that CpG DNA may be a therapeutic candidate for treatment of Alzheimer disease. They report their data in the November 2009 issue of The American Journal of Pathology.

Alzheimer disease is the most common form of dementia, affecting approximately 1.6% of the population in the United States (nearly 19% in the 75-84 age group). It is an incurable, degenerate, and terminal disease thought to be caused by accumulation of oligomeric amyloid β (oAβ).

Microglia are the resident immune cells in the central nervous system; they remove damaged neurons, plaques, and infectious agents from the brain and spinal cord. Microglia cluster around senile Aβplaques in Alzheimer disease patients; however, the role of microglia in oAβtoxicity remains unclear. Doi et al discovered that microglial activation with unmethylated CpG DNA, which binds to an immune receptor on microglia, prevented oAβtoxicity and enhanced oAβ peptide clearance in culture. Furthermore, injection of CpG DNA directly into the brain mitigated both cognitive impairment and learning defects in a mouse model of Alzheimer disease. CpG DNA may therefore be a therapeutic candidate for treatment of Alzheimer disease.

Dr. Doi and colleagues conclude that "CpG, especially class B and C, may also be effective therapeutic agents against oAβ1-42 neurotoxicity in [Alzheimer disease]."


Story Source:

The above story is based on materials provided by American Journal of Pathology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M, Doi M, Michikawa M, Takeuchi H, Suzumura A. Microglia Activated with the Toll-Like Receptor 9 Ligand CpG Attenuate Oligomeric Amyloid β Neurotoxicity in in Vitro and in Vivo Models of Alzheimer's Disease. American Journal Of Pathology, 2009; DOI: 10.2353/ajpath.2009.090418

Cite This Page:

American Journal of Pathology. "CpG DNA Therapy For Alzheimer Disease." ScienceDaily. ScienceDaily, 22 October 2009. <www.sciencedaily.com/releases/2009/10/091022071331.htm>.
American Journal of Pathology. (2009, October 22). CpG DNA Therapy For Alzheimer Disease. ScienceDaily. Retrieved May 27, 2015 from www.sciencedaily.com/releases/2009/10/091022071331.htm
American Journal of Pathology. "CpG DNA Therapy For Alzheimer Disease." ScienceDaily. www.sciencedaily.com/releases/2009/10/091022071331.htm (accessed May 27, 2015).

Share This Page: